PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
1.33%
Cash & equivalents yoy growth below half the Medical - Pharmaceuticals median of 9.68%. Philip Fisher would caution that the company is draining cash relative to peers. Scrutinize free cash flow or additional borrowing.
100.00%
Short-term investments yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt might see stronger near-cash accumulation as an opportunity. Check yields vs. peers.
1.33%
Below half the Medical - Pharmaceuticals median of -0.21% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
No Data
No Data available this quarter, please select a different quarter.
2.30%
Inventory growth near Medical - Pharmaceuticals median of 3.05%. Charlie Munger sees standard industry practice. Check for normal demand patterns.
53.72%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
2.64%
Near the Medical - Pharmaceuticals median of 2.73%. Charlie Munger sees typical short-term asset management among peers.
2.56%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.12%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
4.69%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
4.69%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
-100.00%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
-100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
45.54%
Above 1.5x Medical - Pharmaceuticals median of 0.34%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
2.26%
≥ 1.5x the Medical - Pharmaceuticals median of 0.31%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
2.44%
≥ 1.5x the Medical - Pharmaceuticals median of 0.95%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
1.47%
Payables growth 1.1-1.25x Medical - Pharmaceuticals median of 1.32%. John Neff wonders if the company is pushing out payments more than peers.
-5.43%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-46.05%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-62.69%
≥ 1.5x the Medical - Pharmaceuticals median of -0.05%. Joel Greenblatt sees a robust subscription base vs. peers.
141.47%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
2.19%
1.25-1.5x Medical - Pharmaceuticals median of 1.67%. Guy Spier is cautious about bigger short-term obligations.
-17.96%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
67.79%
Above 1.5x Medical - Pharmaceuticals median of 2.48%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-8.53%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
0.92%
Above 1.5x Medical - Pharmaceuticals median of 0.42%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
7.34%
≥ 1.5x Medical - Pharmaceuticals median of 1.20%. Joel Greenblatt sees stronger retained profit growth vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.23%
≥ 1.5x Medical - Pharmaceuticals median of 1.68%. Joel Greenblatt sees stronger equity growth vs. peers.
2.44%
≥ 1.5x Medical - Pharmaceuticals median of 0.95%. Joel Greenblatt sees more aggressive expansions than peers.
-100.00%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-36.39%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-24.87%
Above 1.5x Medical - Pharmaceuticals median -1.35%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.